Chapman University

Chapman University Digital Commons
Pharmacy Faculty Articles and Research

School of Pharmacy

2006

Cost Prevention of HIV
Jerika Lam
Chapman University, jlam@chapman.edu

Follow this and additional works at: http://digitalcommons.chapman.edu/pharmacy_articles
Part of the Other Chemicals and Drugs Commons, Other Pharmacy and Pharmaceutical
Sciences Commons, Pharmaceutical Preparations Commons, Pharmaceutics and Drug Design
Commons, and the Virus Diseases Commons
Recommended Citation
Lam JT. Cost Prevention of HIV. California Pharmacist Journal 2006; LIII(1):26-30.

This Article is brought to you for free and open access by the School of Pharmacy at Chapman University Digital Commons. It has been accepted for
inclusion in Pharmacy Faculty Articles and Research by an authorized administrator of Chapman University Digital Commons. For more information,
please contact laughtin@chapman.edu.

Cost Prevention of HIV
Comments

This article was originally published in California Pharmacist Journal, volume 53, issue 1, in 2006.
Copyright

California Pharmacists Association

This article is available at Chapman University Digital Commons: http://digitalcommons.chapman.edu/pharmacy_articles/462

Clinical Knowledge,Research,
Clinical Therapeutics

•

ion

by Jerika T. Lam, PharmD

Introduction

High Costs Associated w ith HIV Therapy

ince the introduction of hig hly active antiretroviral therapy
(HAART) in the late 1990s, management of patients with
human immunodefi cien cy virus (HIV) infection has improved
where they are living longer and with fewer incidences ofopportunistic
i!Jnesscs. Furthermo re, signifi cant progress has been made in the
understand ing of the disease, the ability to quantify viral load and
correlate with clinical outco mes, genotypic and phenotypic resistance
assays desig ned to assess viral susceptibility, and a heightened awareness
and appreciation of the importance oftreatment adherence to ensure
virologic suppression.' In spite of the benefits that HIV- infected
patients may have acq ui red in terms of more antiretroviral agents to
select from and with mo re antiviral potency, the newer HAART
regimens should no t be overlooked as simple and tolerable medications. In fact, HAART regim ens are ever more complex and challenging because of the hig h pi ll burden, drug-drug or drug-food in teractions, formu lation characteristics, and long-term drug class-associated
side effects. While the goal of HIV therapy is to achieve maximal vira.l
load suppression to undetectable levels ( <50 copies/ml) and to improve
and stabilize the immune system (CD4 cell count >250 cells/mm 3),
successful pharm acologic management has become difficult due to a
continued high rate of treatmentnon-adherence. C onsequently, viral
resistance to several I-IAART reg imens inevitably develops, which
ultimately leads to drug fa ilure.

Drug therapy, hospitalizations, and other comorbidities or
coinfections (e.g. hepatitis C) all affect the cost and health care
utilization. Published g uidelines fro m the Department ofl-lealth and
Human Services (DHHS) presently recommend at least a three-drug
antiretroviral regimen as the standard ofcare for the treatment ofH I Vinfected patients. HIV medications can be expen sive, where prices for
nucleosides range from approximately $2,500 per perso n, per year
compared to $8,000 per person, per year for those receiving a protease
inhibitor agent. Therefo re, one could imagine the hig h costs associated
with combination HIV therapy.
Several clinical trial s have looked at the cos t-effectiveness of
combination HIV therapy, cost associated with life expectancy, li fe
expectancy adjusted for the qualityoflife, lifetime direct medical cos rs,
and cost effectiveness per quality-adjusted year of life gained. For
instance, data from the A IDS Clinical Trial Group (ACTG) 320
delineate the cost differences between those H I V-infected patients
who were treated on a three-drug reg imen versus those who were
untreated. The ACTG 320 trial showed that HIV-in fected patients
who had received zidovudine (AZT, ZDV), lamivudine (3TC), and
indinavir (IDV) had an estimated per-person lifetime cost of$ 77,300
compared to $45,460 for those infected patients not receiving therapy.
However, the life expectancy adjusted for the quality of li fe in those
receiving therapy was 2.91 years versus 1.53 years in the un treated
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group. The incremental co r per qualiry-adjusred year oflife gained
was $23,000 for rhe treated group versus untreated group. 2 I n comparison, rhc}ohns H opkins HIV C li nic cohort trial demonstrated that
the life expectancy adjusted for rhe qualiry oflife increased from 2.92
to 4.43 years, and per person lifetime costs increased from $54,150 to
$80,460 fo r those receiving the 3-drug regimen (AZT + 3T C + lD V)
as compared ro the untreated g roup. The incre1m:ntal cost perqualiryadjusted yearoflife gained, as compared with the untreated group, was
Sl 7,000.3 On a si milar note, Freedberg er al. reported that, even
though, combination Hl V therapy is costly, it is more cost effective
than many other therapies such as the treatment ofhypercholesrerol.:mia ($47,000 per year of life gained), radiation therapy for early
stage breast cancer ($30,000 per quality-adjusted year oflife gained),
and dialysis in patients expected to live for less than six mo nths
(Sl 50,000 per quality-adjusred year of life gained).' T hese large,
randomized clinical trials help ro shed light into rhe cos rs and benefits
of<lrugexpendirures for HI V-infected patients. H owever, they d o nor
incorporate the cosrs of orher exrernal, bur very imporrant variables
such as long-term antirerroviral drug side effecrs and roxicities, routine
care (e.g. genotypic and phenotypic resistance tests, viral loads, and
CD4 cell counts), effects of inrerventions and cools designed to
improve medication adherence and to reduce the rate of treatment
fai lure.• T hese costs continue to requi re further elucidation.

Benefits of HIV therapy
Presently, several investigators have reported improved virologic
and clinical outcomes for t hose who were Hl V-in fecrcd and were
initiated on combination H I V regimens. From these trials, enrolled
parienrs who were appropriarely treated benefited from decreased
incidences of oppo rtun istic infections, hospitalizations, and morral iry.1 Interestingly, though, one must remember that clinical trials

represent a more ideal setting than what actually occurs in clinical
practice. For instance, in a clinical trial , there are several factors that
buttress the study design from fai ling such as the enrollment of
motivated patients, consistent cou nseling of the study medications,
and regulated monitoring and follow-up from various health d isciplines.

Challenges in the Management of HIV
Patient adherence to HI V d rugs continues to remain the ultimate
challenge towards successful management ofHI V. At the present, the
complexity of HIV regimens, including their intolerable side effects
(e.g. gastrointestinal, CNS, and neuromuscular)challenge health care
providers to successfully help H I V-infected patients attain undetectable viral loads and an increased CD4 cell count. Evidence reports rhar
poor adherence roHI V regimens results in an increased likelihood for
developing viral resistance, clinical complications, and increased
mo rtality. 5 7 Several studies have reported that H I V drug side effects
pose as an infrequen r reason fo r poor adherence. Gifford er al showed
that organizational difficulties (e.g. roo busy, forgetfulness, away from
home, change in routine) and emotional issues were rhe mosrcommon
reasons fo r missed doses among their patients, which comprised
primarily ofmen (86%).8 I n studies that had looked at barriers ro H I V
regimen adherence among wo men, depressive symproms, adverse life
eve nts, HIV- related stress, and care-giving commitments were significant facrors.9 · 10 Wilson et al. reported rhar among 895 women
enrolled in their study, poor adherence was more associated to
intravenous drug use, smoking, and having a lower quality of life. 11
Laine eral. found rharamong the 682 pregnant H IV-infected women
evaluated for adherence, the adjusted odds ratio (AO R) for adherence
was 70% lower than for older women (AO R, 0.34; 95% C l , 0. 12-0. 90)
and 50% lower (Pvalue = 0.01) for black or Hispanic women versus

Table 1. FDA-Approved Antiretroviral Agents
Nuc/eoside Reverse Transcriptase Inhibitors (NRT/s)
Generic Name
Brand Name

Numbero Pi s/Capsu es Dai y

Usual A u tDosages

Abacavir (ABC)
D1danosme (ddl)

Ziagen"
Videx•. Videx• EC

Emtr1c1tabme (FTC)
Lam1vudine (3TC)
Stavudine (d4T)
Tenofovir (TDF)
Zalrnabme (ddC)
Zidovudine (AZT, ZDV)

Emtnva'"'
Epivir"
Zerit"
Vi read"
Hivid"
Retrovir0

300 mg BID or 600 mg
>60 kg: 200 mg BID or
<60 kg: 125 mg BID or
200 mg daily
150 mg BID or 300 mg
>60 kg : 40 mg BID<60
300 mg daily
0.75 mg TIO
200 mg TIO or 300 mg

Fixed-Dose Combination NRTls
AZT + 3TC
AZT + 3TC + ABC
ABC + 3TC
TDF +FTC

Comb1v1r•
Triz1v1r•
Epzicom•
Truvada 1"'

1
1
1
1

daily
400 mg daily
250 mg daily
daily
kg: 30 mg BID

1
1-2
2

BID

3
2-6

1

tab BID
tab BID
tablet daily
tablet daily

Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTls)
Delavirdine (DL V)
Resrnpto~
EfaVlfenz (EFV)
Sust1va•
Nevirapme (NVP)
Viramune•

400 mg TIO or 600 mg BID
600 mg QHS
200 mg BID

Protease Inhibitors (Pis)
Amprenavir (APV)
Atazanav1r (ATV)
Fosamprenav1r (FPV)
lndinavir (IDV)
Lopinavir/Ritonav1r (LPV/RTV)
Nelfmavir (NFV)
R1tonaV1r (RTV)
SaquinaVlf-HGC (hard gel capsule)
Tipranavir

Agenerase•
Reyataz"
Lexiva1"'
Crix1van•
Kaletra"
V1racept•
Norvir"
lnv1rase"
Aptivus<1>

1200 mg BID
400 mg daily
1400 mg BID
800 mg QBH
3 capsules BID
1250 mg BID
600 mg BID
2000 mg daily + RTV 100 mg daily
500 mg BID + RTV 200 mg BID

Entry Fusion Inhibitor
EnfuV1rt1de (T-20)

Fuzeon '"'

90 mg SQ BID
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1-2
1-2

2
2

6
1-3
2
16
2
4
6-1 2

6
4
12
5

8
2
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Table 2. DH HS Guidelines for
Initiation of Therapy32
Clinical Catego
Symptomatic•
Asymptomatic
Asymptomatic

CD4+ Cell Count and Plasma HIV-1 RNA
Any value
CD4+ <200 cells/mmi
CD4+ >200 cells/mm3 but <350 cells/mm3

Asymptomatic

CD4+ >350 cells/mm3 & plasma HIV-1
RNA > 100,000 copies/ml

Asymptomatic

CD4 + >350 cells/mm3 and HIV-1
RNA <100,000 copies/ml

Recommendation
Treat
Treat
Treatment should
be offered
Some clinicians defer
therapy and monitor
frequently
Defer treatment

*AIDS-defining illnesses or malignancies and AIDS wasting
DHHS = Department of Health and Human Services

white women. 12•1l O f note, younger individuals, women, persons of
minorityethnic backgrounds, and patients without health or Medicaid
insurance were less likely to report good treatment adherence. 14
Similarly, other studies reported that femal e sex, younger age, African-American descent, alcohol abuse, and intravenous drug use were
associated with poor treatment adherence.6· 11- 17
While the goals of HIV therapy arc to achieve maximum viral
suppression and to mai ntain a robust immune system, facto rs such as
viral mutations, poor drug absorption, sub-optimal drug exposures,
d rug-drug interactions, and non-adherence pose significant challenges fo r HIV pharmacotherapy specialists such as pharmacists. 18 It
has been reported that greater than 95% treatment adherence is crucial
for achieving satisfactory virologic su ppression. 19 ln order to ensure
that HIV- in fected patients arc adherent to their treatments, pharmacists should employ tools, such as medication counseling, pill counts,
appropriate dosing freq uencies, moni toring for side effects and d rugdrugordrug- food interactio ns, therapeutic mo nitoring of d rug levels,
and phone fo llow-ups for naive- treated patients or those on complex
regi mens. Reiterating the reasons reported from several ofthe clinical
trials d iscussed earl ier in this article, fac tors that have been suggested
to lead to treatment no n-adherence include psychosocial facto rs (e .g.
depression, alcohol abuse, and illicit or intravenous d rug use), education factors (e .g. comprehension ofthe H IV di sease, its progression if
poorly treated, opportuni stic infectio ns, and the importance of HIV
therapy), provider and healthcare-related factors (e.g. paticnttrust in
the clinicians and medical staff), and clinical factors (e.g. pill burden,
administration frequency, and drug toxici ties). 18

ro moderate peripheral neuropathy. The incidence of mild to moderate peripheral neuropathy eou ld oeeur:inytime during HIV treatment,
and may become ameliorated with low-dose
tricyelic antidepressants (e.g. am itriptyline),
anticonvulsants (e.g. gabapentin or lamotrigine),
or with topical agents (e.g. capsaicin cream) ifit
persists. Abacavir (ABC) has been associated
with a potentially fatal skin rash, also termed
"abacavir hypersensitivity reaction," with manifestat ions such as severe nausea, fatigue, fever,
and/or a blistering rash. Occurrence of these
symptoms necessitates immediate discontinuation of abacavir. Re-challenge of patients who
have experienced o r suspected to have had an
"abacavir hypersensitivity reaction" is contrai nd icated.20

Non-nucleoside Reverse T ranscriptase
Inhibitors
Non-nucleoside reverse transcriptase inhibitors (NNRTis) have
been associated with dcrmatologic manifestations such as skin rash.
The rashes arc usually mild and could often be treated with an
antihistam ine agent (e.g. I3enadryi-). H owever, life-threatening and
fatal rashes have been reported, where their manifes tations closely
resemble Stevens-J o hnson Syndrome.21 When these severe rashc
occur, d iscontinuation of the suspected agent is imperative. Efavi rcnz
is unlike delavirdine and nevirapine, where it has been reported to cause
transient CNS effects that include vivid dreams o r nightmares,
somnolence, d izziness, and/or d iffic ul ty concentrating. Most of these
side effects usually resolve between one to three weeks.22

Protease Inhibitors
C lass adverse effects to the protease inhibitors (Pls) may be
associated with long-term metabo lic complications, which may manifest as lipodystrophy (abnorm al fat redistribution), glucose intolerance, and hypcrlipidcmia. 23 -2• Adverse effects ofPis include primarily
the gastrointestinal system, where nausea, vom it ing, bad taste, bloating, and diarrheaoecur frequently in the initial weeks ofdrug therapy.
Hepatitis, hyperbi lirubincmia, nephrolithiasis, and paresthcsias have
been reported, however, their occurrences arc not common. 25 i ;

Fusion Inhibitor
Enfuvirti de

(T-20,

FuzeonT~ 1 ) iscurren tly theonly

Antiretrovirals and Adverse Effects
There are certain toxicities that persist and become more evident
with prolonged use (over years). These drug-associated toxicities arc
frequently class-related.Table 1 illustrates FDA-approved antiretroviral
agents that are presently available. Adverse side effects may occur early
in therapy and become transient. M any ofthe antiretroviral agents' side
effects are common and arc manageable with patient counseling,
adj unctive treatments, and careful dose adjustment. 18 For in stance,
nausea and/or vomiting could be managed by taki ng the antiretroviral
agent with food o r at bedtime. Si milarly, frequent diarrheal episodes
could be managed with ingestion of over- the-counter calcium containing supplements (e.g. Tum s) or Immodium". Severe diarrhea
could be further managed with prescriptio n Lomotil ".

agent available for the entry
fu sion inhibitor class. Furthermore, it is the on ly injectable antiretroviral agent that
is administered subcutaneously. Common adverse effects from this agent include
myalgias, fatigue, nausea, and
injection site reactions (redness, itching, pain, swelling or
tenderness). H ardened skin or
bumps do occur, but not as
frequent as the other side effects.

Nucleoside Reverse Transcriptase Inhibitors
As a class, nucleoside reverse transcriptase inhibitors (NRTis) have
been associated with mitochondrial toxicities, which could manifest as
mild peripheral ncuropathy to life - threaten ing lactic acidosis.
Didanosine (ddl ), stavudinc (d4T), and zalcitabinc (ddC), otherwise
termed t he "d" d rugs, have been reported with increased rates of mild
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Table 3. DH HS Recommendations for ARV
Regimens in Treatment Na"ive Patients32
Preferred Regimens
NNRTl-Based

Regimens
EFV + (3TC or FTC) + (AZT or TDF)

Pl-Based
Alternative Regimens
NNRTl-Based

Kaletra"' + (3TC or FTC) + AZT
Regimens
•EFV + (3TC or FTC) + (ABC or ddl or d4T)

Pl-Based

3 NRTl-Based

Comments
EFV 1s not recommended in 1" trimester of pregnancy or
1n women with high pregnancy potential
Comments
EFV 1s not recommended in 1• trimester of pregnancy or
in women with high pregnancy potential

•NVP + (3TC or FTC) + (AZT or ABC or ddl or d4T or TDF)
•ATV+ (3TC or FTC) + (AZT or ABC or ddl or d4T)
or (TDF + RTV 100 mg/day)
•FPV + (3TC or FTC) + (AZT or ABC or ddl or d4T or TDF)
•FPV/RTV + (3TC or FTC) + (AZT or ABC or
ddl or d4T or TDF)
•IDV/RTV + (3TC or FTC) + (ABC or ddl or d4T or TDF)
•NFV + (3TC or FTC) + (AZT or ABC or ddl or d4T or TDF)
•SQV/RTV + (3TC or FTC) + (AZT or ABC or ddl or d4T or TDF)
ABC + AZT + 3TC (Trizivii4')

dard H JV care (Table 3). Individualized H IV regimens should be
considered so to tailor to each patient's specific nct:ds such as ability
to swal low large sized capsules, tolerability of common side effects,
drug interactions with concom itant medications, convenience and
adherence potential. Initial antiretroviral regimens should include a
nucleoside reverse transcriptase inhibitor (N RT I) agenr combined
with agen ts from eithera non-nucleoside reverse transcriptase inhibitor (NN RTl) class or protease inhibitor (Pl) class.

Recommended only when a preferred or an alternative
NNRTI- or Pl-based regimen cannot or should not be
used

become ever more complex, and have made pharmacologic assessment
ofth e patient vital in HIV management. HI V pharmacists are poised
to significantly impact vi rologic outcomes in H I V therapy by evaluating the patients' complex drug regimens, practice appropriate
adherence intervenrions, and monitor and manage drug interactions
and drug toxicities. I n doing so, HIV pharmacists could help ensure the
fundamental goals of H IV therapy: vi rologic suppression and an
improved immune system.

The Role of the Pharmacist
Pharmacists have been providing pharmaceutical care since the
AlDS epidemic. 18 They have been documenting activities to enhance
adherence; providing written, individualized medication calendars,
organizing pill boxes, giving out beepers,28 performing telephone
follow-up.29 In addition, they could assess treatmenr adherence,
evaluate potential drug-drug or drug-food interactions, monitor and
manage potential drug-associated toxicities with adjunctive treatments, recommend appropriate dosages, and engage in educational
patient counseling. More imporrantly, the intensive training that
pharmacists receive in pharmacokinetics and pharmacodynamics
allow them to help clinicians optimize patient HIV regimens. Since
therapeutic efficacy is associated with the plasma levels of several
antiretroviral agenrs, primarily the NN RTI and PI agents, interpretation of these conce ntrations remains essential, bur challenging
towards optimizing HIV rherapy.18
Evidence suggests that interventions by HIV pharmacists have
improved virologicoutcomes in HIV-infected patients. One study had
evaluated rhe impact of pharmacists' interventions on improving
patients' adherence to their H IV regimens. Among thoseexperiencedtreated patients on salvage therapy, 36% showed a clin ical significant
viral response. These patients have reported receiving adherence
counseling sessions with an HIV pharmacist.30 H JV clinics that
implement therapeutic drug mon itoring (TDM) programs have been
designed to integrate the pharmaceutical care from H IV pharmacists
so to ensu re improved adherence and successful virologic suppression.31

Conclusion
Since the developmentofHAART in 1996, the AI DS com munity
has wi tnessed improvemenrs in the quality of life and a significant
decrease in morbidity and mortality from AIDS-related ill nesses.
Improvements in the development of an tiretroviral therapy have
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